MX2023000919A - Inhibidores de factores del complemento y usos de los mismos. - Google Patents
Inhibidores de factores del complemento y usos de los mismos.Info
- Publication number
- MX2023000919A MX2023000919A MX2023000919A MX2023000919A MX2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A MX 2023000919 A MX2023000919 A MX 2023000919A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- disclosed
- complement factors
- disease
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/650947—Six-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054064P | 2020-07-20 | 2020-07-20 | |
| PCT/US2021/042198 WO2022020244A1 (en) | 2020-07-20 | 2021-07-19 | Inhibitors of complement factors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000919A true MX2023000919A (es) | 2023-04-19 |
Family
ID=79729495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000919A MX2023000919A (es) | 2020-07-20 | 2021-07-19 | Inhibidores de factores del complemento y usos de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11814404B2 (https=) |
| EP (1) | EP4185592A4 (https=) |
| JP (1) | JP7793595B2 (https=) |
| KR (1) | KR20230041758A (https=) |
| CN (2) | CN116947903A (https=) |
| AR (1) | AR123011A1 (https=) |
| AU (1) | AU2021311455A1 (https=) |
| BR (1) | BR112023001007A2 (https=) |
| CA (1) | CA3186022A1 (https=) |
| CL (1) | CL2023000191A1 (https=) |
| CO (1) | CO2023000683A2 (https=) |
| IL (1) | IL299840A (https=) |
| MX (1) | MX2023000919A (https=) |
| PE (1) | PE20231435A1 (https=) |
| PH (1) | PH12023550153A1 (https=) |
| TW (1) | TW202216168A (https=) |
| UY (1) | UY39331A (https=) |
| WO (1) | WO2022020244A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022020244A1 (en) | 2020-07-20 | 2022-01-27 | Annexon, Inc. | Inhibitors of complement factors and uses thereof |
| IL314164A (en) | 2022-01-14 | 2024-09-01 | Annexon Inc | Inhibitors of complement factors and their uses |
| AR131723A1 (es) * | 2023-01-30 | 2025-04-23 | 5Metis Inc | Compuestos que contienen boro y sus usos |
| WO2024254704A1 (en) * | 2023-06-15 | 2024-12-19 | The Governors Of The University Of Alberta | Hemiboronic heterocyclic compounds and uses thereof |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965583A (en) | 1997-04-24 | 1999-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted imidazoles useful in the treatment of inflammatory disease |
| EP1971664B1 (en) * | 2006-01-13 | 2015-09-09 | LG Chem, Ltd. | Emitting materials and organic light emitting device using the same |
| KR20100031723A (ko) | 2007-07-07 | 2010-03-24 | 이데미쓰 고산 가부시키가이샤 | 크리센 유도체 및 이를 이용한 유기 전계 발광 소자 |
| KR101233377B1 (ko) | 2008-12-30 | 2013-02-18 | 제일모직주식회사 | 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자 |
| WO2013049332A1 (en) * | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| WO2015003146A1 (en) * | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| DK3019240T3 (da) | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| TWI532741B (zh) | 2013-09-04 | 2016-05-11 | 喜星素材股份有限公司 | 含吡唑之多環化合物及使用其之有機發光裝置 |
| KR101635154B1 (ko) | 2014-08-28 | 2016-06-30 | (주)더블유에스 | 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자 |
| KR102233296B1 (ko) * | 2014-11-18 | 2021-03-29 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| AR103397A1 (es) * | 2015-01-13 | 2017-05-10 | Syngenta Participations Ag | Oxoborazoles microbicidas |
| US10111885B2 (en) * | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| KR101981245B1 (ko) | 2015-10-27 | 2019-05-22 | 주식회사 엘지화학 | 고리 화합물 및 이를 포함하는 유기 발광 소자 |
| KR101806464B1 (ko) | 2015-11-19 | 2017-12-07 | (주)랩토 | 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자 |
| KR102496411B1 (ko) | 2016-01-06 | 2023-02-06 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2019240471A1 (ko) | 2018-06-11 | 2019-12-19 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2020032428A1 (ko) * | 2018-08-09 | 2020-02-13 | 덕산네오룩스 주식회사 | 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치 |
| CN109574917B (zh) | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
| CN109574910B (zh) * | 2018-12-19 | 2021-07-02 | 山西大学 | 一种咔唑衍生物mcab及其制备方法和应用 |
| CN111087387B (zh) | 2019-12-26 | 2022-04-29 | 厦门天马微电子有限公司 | 一种有机化合物、显示面板及显示装置 |
| CN111423390A (zh) | 2020-03-30 | 2020-07-17 | 北京燕化集联光电技术有限公司 | 一种新型结构化合物及其应用 |
| CN111662309B (zh) | 2020-07-10 | 2021-11-09 | 北京燕化集联光电技术有限公司 | 一种多杂环结构化合物及其应用 |
| WO2022020244A1 (en) | 2020-07-20 | 2022-01-27 | Annexon, Inc. | Inhibitors of complement factors and uses thereof |
| CN113045585A (zh) | 2021-03-16 | 2021-06-29 | 吉林奥来德光电材料股份有限公司 | 一种有机稠环化合物及其制备方法和应用 |
| CN113831332B (zh) | 2021-10-29 | 2024-06-18 | 长春海谱润斯科技股份有限公司 | 一种含氮杂环衍生物及其在有机电致发光器件中的应用 |
| IL314164A (en) | 2022-01-14 | 2024-09-01 | Annexon Inc | Inhibitors of complement factors and their uses |
-
2021
- 2021-07-19 WO PCT/US2021/042198 patent/WO2022020244A1/en not_active Ceased
- 2021-07-19 CN CN202310870524.5A patent/CN116947903A/zh active Pending
- 2021-07-19 EP EP21845924.6A patent/EP4185592A4/en active Pending
- 2021-07-19 AU AU2021311455A patent/AU2021311455A1/en active Pending
- 2021-07-19 KR KR1020237005805A patent/KR20230041758A/ko active Pending
- 2021-07-19 PE PE2023000109A patent/PE20231435A1/es unknown
- 2021-07-19 JP JP2023503413A patent/JP7793595B2/ja active Active
- 2021-07-19 CN CN202180059041.6A patent/CN116261564A/zh active Pending
- 2021-07-19 AR ARP210102028A patent/AR123011A1/es unknown
- 2021-07-19 IL IL299840A patent/IL299840A/en unknown
- 2021-07-19 CA CA3186022A patent/CA3186022A1/en active Pending
- 2021-07-19 MX MX2023000919A patent/MX2023000919A/es unknown
- 2021-07-19 US US17/379,334 patent/US11814404B2/en active Active
- 2021-07-19 PH PH1/2023/550153A patent/PH12023550153A1/en unknown
- 2021-07-19 BR BR112023001007A patent/BR112023001007A2/pt unknown
- 2021-07-20 UY UY0001039331A patent/UY39331A/es unknown
- 2021-07-20 TW TW110126637A patent/TW202216168A/zh unknown
-
2023
- 2023-01-19 CL CL2023000191A patent/CL2023000191A1/es unknown
- 2023-01-20 CO CONC2023/0000683A patent/CO2023000683A2/es unknown
- 2023-10-04 US US18/376,526 patent/US12509474B2/en active Active
-
2025
- 2025-11-20 US US19/395,200 patent/US20260070932A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000191A1 (es) | 2023-09-08 |
| US20240109920A1 (en) | 2024-04-04 |
| UY39331A (es) | 2022-02-25 |
| AU2021311455A1 (en) | 2023-02-16 |
| CN116947903A (zh) | 2023-10-27 |
| CA3186022A1 (en) | 2022-01-27 |
| BR112023001007A2 (pt) | 2023-03-28 |
| IL299840A (en) | 2023-03-01 |
| PE20231435A1 (es) | 2023-09-14 |
| US11814404B2 (en) | 2023-11-14 |
| EP4185592A1 (en) | 2023-05-31 |
| CO2023000683A2 (es) | 2023-01-26 |
| AR123011A1 (es) | 2022-10-19 |
| EP4185592A4 (en) | 2024-08-21 |
| US12509474B2 (en) | 2025-12-30 |
| JP7793595B2 (ja) | 2026-01-05 |
| JP2023534974A (ja) | 2023-08-15 |
| KR20230041758A (ko) | 2023-03-24 |
| US20220048930A1 (en) | 2022-02-17 |
| PH12023550153A1 (en) | 2024-03-18 |
| WO2022020244A1 (en) | 2022-01-27 |
| US20260070932A1 (en) | 2026-03-12 |
| TW202216168A (zh) | 2022-05-01 |
| CN116261564A (zh) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550153A1 (en) | Inhibitors of complement factors and uses thereof | |
| JOP20240216A1 (ar) | مثبطات kras g12c | |
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| JOP20210268B1 (ar) | عوامل تعديل منظِّم توصيل عبر الغشاء في التليف الكيسي | |
| ZA202006190B (en) | Rimegepant for cgrp related disorders | |
| GEAP202315648A (en) | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| WO2017127430A8 (en) | Irak4 inhibiting agents | |
| JO3789B1 (ar) | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة | |
| PH12021551317A1 (en) | Modulators of trex1 | |
| MX2022005335A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2021010870A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2024005935A (es) | Metodos para aumentar la exposicion al plasma de sepiapterina. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| MY190748A (en) | Tricyclic sulfones as ror? modulators | |
| MX2024015576A (es) | Tratamiento para migra?as | |
| EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
| MX2020008678A (es) | Metodos de uso para derivados de benzotriazol trisustituidos. | |
| MY203645A (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| MX2022007626A (es) | Combinaciones. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| MX2020012980A (es) | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. |